Literature DB >> 29106946

Orodispersible tablets containing taste-masked solid lipid pellets with metformin hydrochloride: Influence of process parameters on tablet properties.

Gustavo Freire Petrovick1, Peter Kleinebudde2, Jörg Breitkreutz3.   

Abstract

Compaction of multiparticulates into tablets, particularly into orodispersible tablets (ODTs), is challenging. The compression of pellets, made by solid lipid extrusion/spheronization processes, presents peculiar difficulties since solid lipids usually soften or melt at relatively low temperature ranges and due to applied mechanical forces. Until now, there are no reports in literature about the development of ODTs based on solid lipid pellets. To investigate the feasibility of producing such tablets, a design of experiment (DoE) approach was performed to elucidate the influence of compression force and amount of two co-processed excipients (Ludiflash® and Parteck® ODT) on properties of the tablets (friability, tensile strength, and disintegration time). ODTs (15 mm, flat-faced) with solid lipid pellets (250-1000 µm in diameter) containing 500 mg of metformin HCl, presenting immediate drug release profile and taste-masked properties, were targeted. During compression, a strong lamination of the tablets containing Parteck® ODT was observed. This phenomenon was prominently observed when high compression forces (≥5 kN) and high excipient amounts (≥40%; w/w) were used. On the other hand, the DoE focused on tablets with Ludiflash® showed better results regarding the production of ODTs. A positive influence of the compression force on the tensile strength and disintegration time of the tablets, regarding specifications of the Ph. Eur., was observed. The increase in the amount of this excipient resulted in fast disintegrating tablets, however, a negative influence on the tensile strength was noticed. After optimization of the parameters and formulation, based on the DoE results and considering the Ph. Eur. specifications for tablets, ODTs based on lipid pellets containing metformin HCl presenting immediate release profile (85% drug release in less than 30 min) and taste-masked properties (determined by an electronic tongue) were successfully obtained.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Compression force; DoE; Lipid pellets; Metformin hydrochloride; Orodispersible tablets; Taste-masking

Mesh:

Substances:

Year:  2017        PMID: 29106946     DOI: 10.1016/j.ejpb.2017.10.018

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  4 in total

1.  Application of Multiple-Source Data Fusion for the Discrimination of Two Botanical Origins of Magnolia Officinalis Cortex Based on E-Nose Measurements, E-Tongue Measurements, and Chemical Analysis.

Authors:  Wenguang Jing; Xiaoliang Zhao; Minghua Li; Xiaowen Hu; Xianlong Cheng; Shuangcheng Ma; Feng Wei
Journal:  Molecules       Date:  2022-06-17       Impact factor: 4.927

2.  Design, Optimization, and Correlation of In Vitro/In Vivo Disintegration of Novel Fast Orally Disintegrating Tablet of High Dose Metformin Hydrochloride Using Moisture Activated Dry Granulation Process and Quality by Design Approach.

Authors:  Alhussain H Aodah; Mohamed H Fayed; Ahmed Alalaiwe; Bader B Alsulays; Mohammed F Aldawsari; El-Sayed Khafagy
Journal:  Pharmaceutics       Date:  2020-06-27       Impact factor: 6.321

3.  Development and Evaluation of Cannabidiol Orodispersible Tablets Using a 23-Factorial Design.

Authors:  Robert-Alexandru Vlad; Paula Antonoaea; Nicoleta Todoran; Emöke-Margit Rédai; Magdalena Bîrsan; Daniela-Lucia Muntean; Silvia Imre; Gabriel Hancu; Lénárd Farczádi; Adriana Ciurba
Journal:  Pharmaceutics       Date:  2022-07-14       Impact factor: 6.525

Review 4.  Orally Dispersible Dosage Forms for Paediatric Use: Current Knowledge and Development of Nanostructure-Based Formulations.

Authors:  Andreea Cornilă; Sonia Iurian; Ioan Tomuță; Alina Porfire
Journal:  Pharmaceutics       Date:  2022-08-03       Impact factor: 6.525

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.